Evolus (EOLS) Cash from Investing Activities (2018 - 2026)
Evolus' (EOLS) quarterly Cash from Investing Activities came in at -$1.7 million in Q1 2026, up 9.13% YoY from -$1.5 million in Q1 2025, and up 21.93% on a QoQ basis from -$2.2 million in Q4 2025.
Evolus (EOLS) Cash from Investing Activities (2018 - 2026) Analysis & Trends
Evolus (EOLS) has 9 years of Cash from Investing Activities data on file, last reported at -$1.7 million in Q1 2026.
- Quarterly Cash from Investing Activities rose 9.13% year-over-year to -$1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.3 million (down 40.68% YoY) and the FY2025 annual result came in at -$8.5 million, down 75.24% from the prior year.
- Cash from Investing Activities grew to -$1.7 million in Q1 2026, from -$2.2 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$216000.0 in Q2 2023 to a low of -$2.3 million in Q2 2025.
- A 5-year average of -$1.1 million and a median of -$1.3 million in 2024 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities tumbled 4380.95% — and 2023, when it soared 74.05%.
- Tracing EOLS's Cash from Investing Activities over 5 years: stood at -$1.4 million in 2022, then soared by 74.05% to -$361000.0 in 2023, then sank by 277.29% to -$1.4 million in 2024, then slumped by 59.03% to -$2.2 million in 2025, then advanced by 21.93% to -$1.7 million in 2026.
- The last three Cash from Investing Activities figures came in at -$1.7 million (Q1 2026), -$2.2 million (Q4 2025), and -$2.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Evolus | 552.49 Mn | 507.32 Mn | 57.18 Mn | -500,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -500,000.00 |
| Jun 30, 2026 | -500,000.00 |
| Mar 31, 2026 | -1.69 Mn |
| Mar 31, 2026 | -1.69 Mn |
| Dec 31, 2025 | -2.17 Mn |
| Dec 31, 2025 | -2.17 Mn |
| Sep 30, 2025 | -2.16 Mn |
| Sep 30, 2025 | -2.16 Mn |
| Jun 30, 2025 | -2.27 Mn |
| Jun 30, 2025 | -2.27 Mn |
| Mar 31, 2025 | -1.86 Mn |
| Mar 31, 2025 | -1.86 Mn |
| Dec 31, 2024 | -1.36 Mn |
| Dec 31, 2024 | -1.36 Mn |
| Sep 30, 2024 | -1.41 Mn |
| Sep 30, 2024 | -1.41 Mn |
| Jun 30, 2024 | -1.25 Mn |
| Jun 30, 2024 | -1.25 Mn |
| Mar 31, 2024 | -797,000.00 |
| Mar 31, 2024 | -797,000.00 |